Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Boehringer Ingelheim Pharma Kg

Ingo Heddesheimer

Rolf Dach

Oliver Meyer

Helmut Heitger

Hermann Mueller-Boetticher

Frieder Gnad

Stefan Schmitt

Ulrich Scholz

Georg Zerban

Siegfried Meineck

Michael Guenter Wohlgemuth

Volker Brenk

Bernhard Schmitz

Seigfried Meineck

An improved method of preparing dabigatran etexilate mesylate (1-salt), is described.

Method for producing dabigatran etexilate methansulphonate

An improved process for preparing dabigatran etexilate, as well as analogous compounds of formula 7, is described.

Process for the manufacture of dabigatran etexilate

The invention relates to a process for the synthesis of the diamine of formula (1) an important intermediate in the synthesis of dabiagtran etexilate. 

Process for the manufacture of an intermediate in the synthesis of dabigatran

The invention provides a process for making compounds of the general formula I: wherein R, R, R, Rand Q are defined as in claim. The compounds of the general formula I are effective inhibitors of HIV reverse transcriptase.

Process for making a non-nucleoside HIV-1 reverse transcriptase inhibitor

Process for preparing vanillylamine or one of the salts thereof by reacting vanillin with hydroxylamine or the salts thereof in the presence of an organic salt, which may optionally be produced in situ, wherein the reaction is carried out in an inorganic or organic acid as diluent, and subsequently hydrogenating the resulting vanillyloxime with hydrogen in the presence of a suitable catalyst and an organic and/or inorganic acid.

Process for preparing vanillylamine hydrochloride

Growing community of inventors

Monzingen, Germany

Ingo Heddesheimer